Waters (WAT) Up 5.4% Since Last Earnings Report: Can It Continue?

Waters (WAT) reported strong second-quarter 2025 results, with non-GAAP EPS of $2.95 and net sales of $771.33 million, both surpassing analyst estimates and growing 12% and 9% year-over-year, respectively. This performance has driven a 5.4% increase in WAT's share price since the last earnings report, outperforming the S&P 500. The company subsequently raised its guidance for both Q3 and full-year 2025, projecting continued earnings and sales growth. Despite the robust results and positive outlook, analyst estimates have shown a downward trend over the past month, resulting in a Zacks Rank #3 (Hold) and an overall 'F' VGM Score, indicating a mixed sentiment for the stock's near-term trajectory.

Analysis

Waters Corporation (WAT) delivered a robust second-quarter 2025, with non-GAAP EPS of $2.95 and net sales of $771.33 million, representing year-over-year growth of 12% and 9%, respectively, and beating consensus estimates. Growth was driven by the core Waters segment (+11% YoY) and particularly strong performance in recurring revenue streams like Chemistry (+17% YoY) and Services (+9% YoY), alongside continued strength in the key Pharmaceutical end-market (+11% YoY). Despite this top-line strength, there are underlying concerns, including a significant year-over-year decline in cash from operations to $41.14 million, a slight 10 basis point contraction in adjusted operating margin, and lagging growth in the Americas region (+2% YoY). In response to the strong quarter, management raised its full-year 2025 guidance, now projecting non-GAAP EPS growth of 9-10% and sales growth of 5-7%. However, a notable disconnect exists between the company's positive report and subsequent market sentiment, as analyst estimates have trended downward post-earnings, culminating in a Zacks Rank #3 (Hold) and a poor overall VGM Score of 'F', suggesting caution despite the stock's recent 5.4% outperformance.

Key Decisions for Investors

• Investors should weigh the company's strong Q2 results and raised full-year guidance against the conflicting signal of downward analyst estimate revisions and a poor 'F' VGM Score, which supports a neutral or 'Hold' position.
• Monitor the company's next earnings report for an improvement in cash from operations, which declined significantly year-over-year, and for signs of acceleration in the lagging Americas and Academic & Government segments.
• Given the stock's 5.4% outperformance since the report, the positive results may be priced in, warranting caution before initiating new long positions until the divergence between company guidance and analyst sentiment resolves.